Lyfegen

Lyfegen, established in 2018 and headquartered in Switzerland, delivers cutting-edge software solutions for the healthcare sector, focusing on pricing, access, and rebate management. The company's offerings significantly alleviate the administrative strain associated with managing intricate drug pricing agreements. By deploying Lyfegen's tools, stakeholders like health insurances, governments, hospital payers, and pharmaceutical companies can optimize rebates and enhance value from existing agreements.

Key to their innovation is the world's largest digital repository of innovative drug pricing models and public agreements. Their advanced drug pricing simulator, a standout feature, allows users to dynamically test and predict complex drug pricing scenarios, revealing comprehensive financial impacts. Operating globally across Europe, North America, and the Middle East, Lyfegen has secured a $5.68M Series A funding round led by aMoon and TX Ventures as of December 2024. This investment underscores confidence in Lyfegen's potential to streamline drug pricing complexities and expand its market influence.